Electrophysiologic effects of intravenous magnesium in patients with normal conduction systems and no clinical evidence of significant cardiac disease

Parenteral magnesium has been used for several decades in the empiric treatment of various arrhythmias, but the data on its electrophysiologic effects in man are limited. We evaluated the electrophysiologic effects of magnesium sulfate (MgSO4) administration in eight normomagnesemic patients with normal mononuclear cell magnesium content, who had no clinically significant heart disease and had normal baseline electrophysiologic properties. After administration of intravenous MgSO4, serum magnesium rose significantly from 1.9 ± 0.1 to 4.4 ± 1.7 mg/dl (p < 0.02). During a maintenance magnesium infusion, we observed significant prolongation of the ECG PR interval (145 ± 18 to 155 ± 26 msec, p < 0.05), AH interval (77 ± 27 to 83 ± 26 msec, p < 0.002), antegrade atrioventricular (AV) nodal effective refractory period (278 ± 67 to 293 ± 67 msec, p < 0.05), and sinoatrial conduction time (60 ± 34 to 76 ± 32 msec, p < 0.02). No significant effect was observed on sinus cycle length, sinus node recovery time, intra-atrial or intraventricular conduction times, QRS duration (during both sinus rhythm and ventricular pacing), QT interval, HV interval, paced cycle length resulting in AV nodal Wenckebach block, AV nodal functional refractory period, retrograde ventriculoatrial (VA) effective refractory period, or atrial and ventricular refractory periods. These findings, in conjunction with the demonstrated ability of magnesium to block slow channels for sodium movement, may provide an explanation of the mechanism by which magnesium exerts its effect in the treatment of atrial and junctional arrhythmias.